732 related articles for article (PubMed ID: 10988075)
1. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Schindler T; Bornmann W; Pellicena P; Miller WT; Clarkson B; Kuriyan J
Science; 2000 Sep; 289(5486):1938-42. PubMed ID: 10988075
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
Nagar B; Bornmann WG; Pellicena P; Schindler T; Veach DR; Miller WT; Clarkson B; Kuriyan J
Cancer Res; 2002 Aug; 62(15):4236-43. PubMed ID: 12154025
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
[TBL] [Abstract][Full Text] [Related]
4. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
Nagar B
J Nutr; 2007 Jun; 137(6 Suppl 1):1518S-1523S; discussion 1548S. PubMed ID: 17513418
[TBL] [Abstract][Full Text] [Related]
5. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
[TBL] [Abstract][Full Text] [Related]
6. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
[TBL] [Abstract][Full Text] [Related]
7. STI-571: an anticancer protein-tyrosine kinase inhibitor.
Roskoski R
Biochem Biophys Res Commun; 2003 Oct; 309(4):709-17. PubMed ID: 13679030
[TBL] [Abstract][Full Text] [Related]
8. A Src-like inactive conformation in the abl tyrosine kinase domain.
Levinson NM; Kuchment O; Shen K; Young MA; Koldobskiy M; Karplus M; Cole PA; Kuriyan J
PLoS Biol; 2006 May; 4(5):e144. PubMed ID: 16640460
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology. Cancer fighter's modus operandi revealed.
Marx J
Science; 2000 Sep; 289(5486):1857-9. PubMed ID: 11012350
[TBL] [Abstract][Full Text] [Related]
10. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
[TBL] [Abstract][Full Text] [Related]
11. A myristoyl/phosphotyrosine switch regulates c-Abl.
Hantschel O; Nagar B; Guettler S; Kretzschmar J; Dorey K; Kuriyan J; Superti-Furga G
Cell; 2003 Mar; 112(6):845-57. PubMed ID: 12654250
[TBL] [Abstract][Full Text] [Related]
12. Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
Cheng WH; von Kobbe C; Opresko PL; Fields KM; Ren J; Kufe D; Bohr VA
Mol Cell Biol; 2003 Sep; 23(18):6385-95. PubMed ID: 12944467
[TBL] [Abstract][Full Text] [Related]
13. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.
Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057
[TBL] [Abstract][Full Text] [Related]
14. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Lin YL; Meng Y; Jiang W; Roux B
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
[TBL] [Abstract][Full Text] [Related]
15. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
16. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
[TBL] [Abstract][Full Text] [Related]
17. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
[TBL] [Abstract][Full Text] [Related]
18. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
Atwell S; Adams JM; Badger J; Buchanan MD; Feil IK; Froning KJ; Gao X; Hendle J; Keegan K; Leon BC; Müller-Dieckmann HJ; Nienaber VL; Noland BW; Post K; Rajashankar KR; Ramos A; Russell M; Burley SK; Buchanan SG
J Biol Chem; 2004 Dec; 279(53):55827-32. PubMed ID: 15507431
[TBL] [Abstract][Full Text] [Related]
19. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
20. ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase.
Xiong YZ; Chen PY
J Mol Model; 2008 Nov; 14(11):1083-6. PubMed ID: 18663490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
